Y-mAbs Therapeutics Inc. (YMAB)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
YMAB Chart
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.21 per share a year ago.
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Y-mAbs Therapeutics Inc. (YMAB) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Y-mAbs Therapeutics Inc. Profile
| - Industry | - Sector | Michael Rossi CEO | NASDAQ (NGS) Exchange | 984241109 CUSIP |
| US Country | 104 Employees | - Last Dividend | - Last Split | 21 Sep 2018 IPO Date |
Overview
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company that has specialized in the development and commercialization of innovative antibody-based therapeutic products aimed at treating cancer. Established in 2015 and based in New York, New York, the company has positioned itself at the forefront of cancer treatment by focusing on novel therapies that address the needs of patients suffering from severe forms of the disease across the United States. Through strategic licensing agreements with institutions like Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology, Y-mAbs has access to cutting-edge technologies and research capabilities to further its mission of delivering groundbreaking cancer treatments.
Products and Services
- DANYELZA
A monoclonal antibody therapy combined with granulocyte-macrophage colony-stimulating factor, specifically designed for the treatment of pediatric patients with high-risk neuroblastoma that is relapsed or refractory. Further development is underway for its application in first-line and third-line neuroblastoma treatment, as well as for relapsed osteosarcoma.
- GD2-GD3 Vaccine
This vaccine is currently in Phase II clinical trials, targeting patients with Stage 4 high-risk neuroblastoma. It represents Y-mAbs’ innovative approach to leveraging the body’s immune response to combat cancer.
- Omburtamab
A murine monoclonal antibody in clinical trials for targeting central nervous system/leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other tumors positive for B7-H3.
- Nivatrotamab
Undergoing Phase I/II clinical trials, Nivatrotamab is being evaluated for its effectiveness in treating refractory GD2 positive adult and pediatric solid tumors, including small cell lung cancer. This therapy exemplifies Y-mAbs’ dedication to expanding its portfolio to address a broader range of cancers.
- Lu-omburtamab-DTPA
Currently in Phase I clinical development, this treatment targets medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. It underscores Y-mAbs’ ongoing investment in developing treatments for difficult-to-treat cancers.
